Cationic and biocompatible polymer/lipid nanoparticles as immunoadjuvants

7Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.

Cite

CITATION STYLE

APA

Pérez-Betancourt, Y., Araujo, P. M., Távora, B. de C. L. F., Pereira, D. R., Faquim-Mauro, E. L., & Carmona-Ribeiro, A. M. (2021). Cationic and biocompatible polymer/lipid nanoparticles as immunoadjuvants. Pharmaceutics, 13(11). https://doi.org/10.3390/pharmaceutics13111859

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free